Journal Information
Vol. 15. Issue 3.
Pages 353-365 (May - June 2009)
Share
Share
Download PDF
More article options
Vol. 15. Issue 3.
Pages 353-365 (May - June 2009)
Artigo Original/Original Article
Open Access
Tuberculose multirresistente: Detecção directa em amostras respiratórias com o método de genética molecular MTBDRplus®
Multidrug-resistant tuberculosis: Rapid molecular detection with MTBDRplus® assay in clinical samples
Visits
5015
Rita Macedo1,
Corresponding author
rita.macedo@csalcantara.min-saude.pt

Correspondência / Correspondence to: Laboratório de Saúde Pública – Micobacteriologia/ Tuberculose, Administração Regional de Saúde de Lisboa e Vale do Tejo, I.P., Rua Pedro Cálmon, n.º 25, 1300-455 Lisboa Tel: +351 213602520 Fax: +351 213602525
, António Amorim1, Edna Pereira1
1 Laboratório de Saúde Pública: Micobacteriologia/ Tuberculose, Administração Regional de Saúde de Lisboa e Vale do Tejo, IP/Public Health Laboratory: Mycobacteriology/Tuberculosis, Regional Health Administration, Lisbon and Tagus Valley Health Authority
This item has received

Under a Creative Commons license
Article information
Resumo

Uma das principais problemáticas no controlo da tuberculose é o aparecimento de casos de tuberculose multirresistente (TB-MR) e tuberculose extensiva-mente resistente (TB-XDR). A detecção precoce da resistência a fármacos, directamente a partir de amostras respiratórias, é essencial para que se assegure o tratamento atempado, adequado e eficaz da tuberculose, bem como para prevenir a disseminação destes casos de especial gravidade.

O nosso objectivo foi avaliar a sensibilidade e comparar os resultados obtidos com um método de genética molecular disponível comercialmente – MTBDRplus® – e o isolamento, identificação e testes de sensibilidade clássicos, directamente a partir de amostras respiratórias. Estudamos 68 amostras, com baciloscopia positiva.

O MTBDRplus® permitiu identificar, directamente a partir das amostras respiratórias, o complexo Mycobacte-rium tuberculosis em todos os casos em que o estudo cultural e a identificação clássica chegaram a esse mesmo resultado. Nas amostras em que culturalmente iso-lámos estirpes sensíveis, com o MTBDRplus® encontrá-mos sempre perfis genéticos do tipo selvagem (63,2%). Relativamente às amostras em que culturalmente isolá-mos estirpes resistentes, com o MTBDRplus® encontrámos sempre perfis genéticos com mutações ou com au-sência do perfil do tipo selvagem (36,8%).

Este estudo permitiu concluir que o MTBDRplus® assegura a detecção rápida de resistências a fármacos em estirpes do complexo M. tuberculosis, com resultados totalmente sobreponíveis aos obtidos com os mé-todos bacteriológicos clássicos.

Rev Port Pneumol 2009; XV (3): 353-366

Palavras-chave:
Tuberculose
multirresistência
diagnóstico laboratorial
Abstract

Nowadays, the greatest concern of tuberculosis control programmes is the appearance of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Rapid determination of drug resistance in clinical samples, with Mycobacterium tuberculosis complex (MTC), is the prerequisite for initiating effective chemotherapy, ensuring successful treatment of the patient and preventing further spread of drug-resistant isolates.

The aim of our study was to determine the sensitivity of the new MTBDRplus® assay in comparison to culture, identification and classic DST, directly from smear-positive clinical specimens.

A total of 68 smear-positive sputum specimens were processed by both the classical mycobacteriological methods and the molecular assay, MTBDRplus®.

MTBDRplus® assay allowed an accurate identification of MTC species by detection of the specific band in all samples, from which we also isolated and identified MTC strains by culture methods. In the samples from which we isolated susceptible strains (63.2%), wild type patterns were found using MTB-DRplus® assay. The samples from which we isolated resistant strains (36.8%) showed specific mutations associated with the correspondent resistant pheno-type.

Our study indicated that this assay allows rapid detection of resistance, always in agreement with classic methods.

Rev Port Pneumol 2009; XV (3): 353-366

Key-words:
Tuberculosis
multi-drug resistance
laboratory diagnosis
Full text is only aviable in PDF
Bibliografia/Bibliography
[1.]
World Health Organization.
Guidelines for the programmatic management of drug resistant tuberculosis. WHO/HTM/TB/2006.361.
World Health Organization, (2006),
[2.]
SVIG-TB, Direcção-Geral da Saúde.
Ponto da situa-ção epidemiológica e de desempenho em 2007, dados preliminares, (2007),
[3.]
World Health Organization.
Antituberculous drug resistance in the World, Report number 3, (2005),
[4.]
M.A. Aziz, A. Wright, A. Laszlo, A. de Muuynck, F. Portaels, A. van Deun, C. Wells, P. Nunn, L. Blanc, M. Raviglione.
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance) an updated analysis.
Lancet, 368 (2006), pp. 2142-2154
[5.]
A. Kochi, B. Vareldzis, K. Styblo.
Multidrug–resistant tuberculosis and its control.
Res Microbiol, 144 (1993), pp. 104-110
[6.]
M.C. Raviglione, M.B. Smith.
XDR Tuberculosis – Implications for global public health.
N Engl J Med, 356 (2007), pp. 656-659
[7.]
World Health Organization.
Addressing the threat of tuberculosis caused by extensively drug resistant Mycobacterium tuberculosis (XDR-TB).
Weekly Epidemiological Record, 81 (2006), pp. 385-396
[8.]
L.M. Parsons, A. Somoskövi, R. Urbanczik, M. Salfinger.
Laboratory diagnostic aspects of drug resistant tuberculosis.
Front Biosci, 9 (2004), pp. 2086-2105
[9.]
P. Coll.
Fármacos con actividad frente a Mycobacterium tuberculosis.
Enferm Infecc Microbiol Clin, 21 (2003), pp. 299-308
[10.]
A. Somoskovi, L.M. Parsons, M. Salfinger.
The molecular basis of resistance to isoniazid, rifampin and pyrazinamide in My-cobacterium tuberculosis.
Respir Res, 2 (2001), pp. 164-168
[11.]
H.A. Shoeb, B.U. Bowman Jr., A.C. Ottolenghi, A.J. Merola.
Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra.
Antimicrob Agents Chemother, 27 (1985), pp. 404-407
[12.]
A.S. Pym, B. Saint-Joanis, S.T. Cole.
Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans.
Infect Immun, 70 (2002), pp. 4955-4960
[13.]
Z. Li, C. Kelley, F. Collins, D. Rouse, S. Morris.
Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs.
J Infect Dis, 177 (1998), pp. 1030-1035
[14.]
A. Banerjee, E. Dubnau, A. Quemard, V. Balasubramanian, K.S. Um, T. Wilson, D. Collins, G. de Lisle, W.R. Jacobs Jr..
InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.
Science, 263 (1994), pp. 227-230
[15.]
R. Macedo, J. Perdigão, I. Portugal, L. Brum.
MDR--TB in Lisbon area: data report from 2004 to 2006.
28th Annual Congress of European Society of Myco-bacteriology (Abstract book), (2007), pp. 37
[16.]
J. Mäkinen, H.J. Marttila, M. Marjamäki, M.K. Viljanen, H. Soini.
Comparison of two commercially available DNA line probe assays for detection of multidrug–resistant Mycobacterium tuberculosis.
J Clin Microbiol, 44 (2006), pp. 350-352
[17.]
C. Piersimoni, A. Olivieri, L. Benacchio, C. Scarparo.
Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonra-diometric systems.
J Clin Microbiol, 44 (2006), pp. 20-28
[18.]
D. Bang, A. Bengård Andersen, V.Ø. Thomsen.
Rapid genotypic detection of rifampin– and isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimens.
J Clin Microbiol, 44 (2006), pp. 2605-2608
[19.]
C. Cavusoglu, A. Turhan, P. Akinci, I. Soyler.
Evaluation of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates.
J Clin Microbiol, 44 (2006), pp. 2338-2342
[20.]
D. Hillemann, M. Weizenegger, T. Kubica, E. Richter, S. Niemann.
Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates.
J Clin Microbiol, 43 (2005), pp. 3699-3703
[21.]
P. Miotto, F. Piana, V. Penati, F. Canducci, G.B. Migliori, D.M. Cirillo.
Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.
J Clin Microbiol, 44 (2006), pp. 2485-2491
[22.]
A. Somoskovi, J. Dormandy, D. Mitsani, J. Rivenburg, M. Salfinger.
Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin.
J Clin Microbiol, 44 (2006), pp. 4459-4463
[23.]
D. Hillemann, S. Rüsch-Gerdes, E. Richter.
Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens.
J Clin Microbiol, 45 (2007), pp. 2635-2640
Copyright © 2009. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?